Want to see AZTA full AI Analyst Report?
AZTA Stock Chart & Stats
$32.95
-$0.65(-2.25%)
At close: 4:00 PM EDT
$32.95
-$0.65(-2.25%)
Day’s Range― - ―
52-Week Range$15.93 - $46.41
Previous Close$28.28
Volume692.82K
Average Volume (3M)1.12M
Market Cap
$1.57B
Enterprise Value$881.45M
Total Cash (Recent Filing)$325.80M
Total Debt (Recent Filing)$53.97M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Nov 17, 2026EPS Estimate
0.12Next Dividend Ex-DateN/A
Dividend Yield0.37%
Share Statistics
EPS (TTM)-2.75
Shares Outstanding43,808,390
10 Day Avg. Volume1,263,559
30 Day Avg. Volume1,123,927
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)0.76
Price to Sales (P/S)2.21
P/FCF Ratio34.28
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue1.44
Enterprise Value/Gross Profit3.26
Enterprise Value/Ebitda-9.12
Forecast
1Y Price Target
$35.00Price Target Upside6.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.52
Revenue Forecast (FY)$639.25M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue BaseA revenue base with more than half recurring can improve visibility and resilience across customer spending cycles. Growth in biorepositories and C&I also supports repeat consumables, service, and repository demand, strengthening customer relationships and providing a durable foundation for future execution.
Conservative Balance SheetVery low leverage and substantial equity provide Azenta with meaningful financial flexibility while it manages operational changes and invests in growth. The strong capitalization reduces refinancing pressure and gives management greater capacity to fund initiatives, absorb execution costs, and preserve strategic options.
Improving Operating ExecutionThe stronger Q3 result and improved full-year outlook indicate better execution and stabilization after earlier pressure. Organic growth across the quarter, combined with higher guidance, can support scale benefits and reinvestment, although the durability of growth still depends on project timing and customer demand.
Bears Say
Persistent Losses And Margin PressureSustained negative margins show that Azenta is not yet converting revenue into consistent profits, limiting internal capital generation and reducing the durability of its growth investments. Recent gross-margin deterioration adds evidence that operating costs, mix, and execution remain significant barriers to earnings improvement.
Automated Stores WeaknessWeak automated-store bookings and unresolved quality remediation can suppress both near-term revenue and Sample Management Solutions margins. Costs, testing, and customer sign-off requirements may extend the recovery period, while the need to address customized systems indicates execution challenges in an important offering.
Multiomics Restructuring RiskClosing laboratories and reducing staff may eventually improve efficiency, but the restructuring creates implementation risk over the next several quarters. Facility exits, asset impairments, and workforce disruption could interrupt customer relationships or service delivery while management consolidates the laboratory network.
Azenta News
AZTA FAQ
What was Azenta’s price range in the past 12 months?
Azenta lowest stock price was $15.93 and its highest was $46.41 in the past 12 months.
What is Azenta’s market cap?
Azenta’s market cap is $1.57B.
When is Azenta’s upcoming earnings report date?
Azenta’s upcoming earnings report date is Nov 17, 2026 which is in 26 days.
How were Azenta’s earnings last quarter?
Azenta released its earnings results on Aug 04, 2026. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.114 by $0.046.
Is Azenta overvalued?
According to Wall Street analysts Azenta’s price is currently Undervalued.
Does Azenta pay dividends?
Azenta pays a Quarterly dividend of $0.1 which represents an annual dividend yield of 0.37%. See more information on Azenta dividends here
What is Azenta’s EPS estimate?
Azenta’s EPS estimate is 0.12.
How many shares outstanding does Azenta have?
Azenta has 43,808,390 shares outstanding.
What happened to Azenta’s price movement after its last earnings report?
Azenta reported an EPS of $0.16 in its last earnings report, beating expectations of $0.114. Following the earnings report the stock price went up 5.609%.
Which hedge fund is a major shareholder of Azenta?
Currently, no hedge funds are holding shares in AZTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Azenta Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (6.22% Upside)
$35.00 (6.22% Upside)
Blogger Sentiment
Bullish
AZTA Sentiment 75%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 402.8K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.56%
12-Months-Change
Fundamentals
Return on Equity
-7.56%
Trailing 12-Months
Asset Growth
-7.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Azenta
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.
AZTA Company Deck
AZTA Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflected a cautious but constructive tone: the company delivered a better-than-expected quarter with solid organic revenue growth (9%), sequential profitability improvement (adjusted EBITDA margin up ~610 bps sequentially) and progress on strategic initiatives (AI-enabled biorepository deployment, modular stores, UKBC integration, and B Medical divestiture). However, meaningful near-term headwinds remain — notably gross margin pressure (overall and in Sample Management Solutions), quality remediation costs ($5M–$6M expected), ongoing Sanger secular decline, negative quarterly free cash flow, and a difficult Q4 comp. Management emphasized disciplined execution and a measured outlook. Overall, positives around execution and a stronger outlook are balanced by persistent margin and demand uncertainties.View all AZTA earnings summariesAZTA Stock 12 Month Forecast
Average Price Target
$35.00
▲(6.22% Upside)
Technical Analysis
Ownership Overview
12.35% Insiders
39.34% Mutual Funds
0.39% Other Institutional Investors
15.20% Public Companies and
Individual Investors